Myelodysplastic Syndrome with Excess Blasts

Myelodysplastic Syndrome with Excess Blasts — Trials · CancerIndex

Clinical trials

Registered studies

76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 23
Recruiting: 12
Ph III recruiting: 0
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00093470	Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission	completed	Phase 3	144	National Cancer Institute (NCI)NIH	3	Jul 14, 2026	clinicaltrials
NCT03092674	Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	completed	Phase 2 / Phase 3	76	National Cancer Institute (NCI)NIH	1	Jan 16, 2025